Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 2nd Preview)
-
Obesity drugs: FDA clears Lilly’s oral GLP-1 Foundayo
The U.S. FDA approved Eli Lilly’s oral GLP-1 receptor agonist orforglipron, marketed as Foundayo, setting up direct commercial competition with Novo Nordisk’s oral obesity pill Wegovy. The approval adds a second once-daily oral option in the expanding anti-obesity market while reducing reliance on injections for some patients. Regulators cleared Foundayo for adults with obesity or overweight plus at least one weight-related comorbidity, in combination with diet and increased physical activity. Lilly is preparing to launch soon after approval. In parallel, coverage of the approval emphasized the market impact of oral convenience—potentially shifting insurer, telehealth, and cash-pay access dynamics as both companies race to broaden adoption. The approvals also come amid heightened scrutiny of GLP-1 product differentiation and comparative messaging in the U.S.
-
Big obesity funding: Ambrosia lands $100M to scale oral GLP-1 program
Ambrosia Biosciences secured $100 million in an oversubscribed Series B round to advance an oral small-molecule GLP-1 candidate aimed at competing in the new oral obesity drug landscape. The Denver-area company said the funding will support clinical development of its lead program and other cardiometabolic pipeline assets. The round was co-led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, according to the report. Ambrosia positions its approach around combinability and convenience versus weekly injectable GLP-1s, following regulatory momentum that broadened oral obesity options. With competitors and peers also racing toward oral incretin-based therapies, the financing underscores how investor focus is shifting beyond injections—toward next-wave formulations that can drive access and adherence at scale.
-
AstraZeneca’s hypophosphatasia enzyme therapy stumbles in pivotal phase
AstraZeneca’s experimental enzyme replacement therapy efzimfotase alfa produced mixed outcomes in three late-stage trials in hypophosphatasia, a rare genetic bone disorder. The results mark another setback in the company’s pursuit of approval in a field where durable efficacy signals are required across multiple endpoints. Efzimfotase alfa has been evaluated in late-stage studies targeting the clinical manifestations of hypophosphatasia. The report highlighted that trial readouts did not deliver a clean path forward. For biotech and pharma stakeholders, the outcome reinforces the high bar for rare-disease registrational programs and the need for consistent efficacy across confirmatory studies.
-
Immunology M&A: Biogen to buy Apellis for $5.6B
Biogen agreed to acquire Apellis Pharmaceuticals for about $5.6 billion, expanding the Massachusetts-based biotech’s immunology and rare-disease portfolio with two marketed assets. The deal gives Biogen access to Empaveli (C3G and primary IC-MPGN) and Syfovre (geographic atrophy secondary to age-related macular degeneration). Under the terms described, Biogen will pay $41 per Apellis share upfront, with additional contingent value right payments tied to Syfovre global net sales milestones. The acquisition is expected to add near-term revenue and commercial infrastructure as Biogen prepares launches including felzartamab. The transaction further signals that large-cap immunology strategy is increasingly being built through buying approved late-stage franchises rather than relying only on internal pipeline execution.
-
Sleep medicine M&A: Lilly agrees to buy Centessa for $6.3B
Eli Lilly agreed to acquire Centessa Pharmaceuticals for about $6.3 billion in upfront cash, adding a clinical-stage portfolio of orexin receptor 2 (OX2R) agonists for sleep-wake disorders. The transaction is set up as Lilly’s next major push beyond obesity into a neuroscience area where multiple players are competing. Centessa’s lead asset, cleminorexton (formerly ORX-750), has shown positive Phase 2a data across narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, positioning the company for potential pivotal trial execution post-close. Lilly’s deal also includes the possibility of additional payments via contingent value rights tied to FDA approvals for clinical candidates. The acquisition reflects how obesity cash flow is being redeployed into other high-unmet-need franchises, while reinforcing a broader industry shift toward neuroscience modalities tied to distinct wake biology mechanisms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.